Teva to pay $2 million in breach of Effexor patent case
This article was originally published in Scrip
Following the lifting of a gag order imposed by an Israeli court, it has emerged that Makhteshim-Agan Industries has been awarded $2 million in settlement of a lawsuit it filed against Teva Pharmaceutical Industries in 2009, which accused the generics manufacturer of breaking a confidential disclosure agreement and stealing trade secrets.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.